ACRO Forecasts Radiologist Surplus
OAK BROOK, Ill--Young physicians seeking careers in radiation on-cology may have severely limited employment opportunities in the foreseeable future, according to the American College of Radiation Oncology (ACRO). The College forecasts that up to 1,000 radiation oncologists will be either underemployed or unemployed shortly after the year 2000.
OAK BROOK, Ill--Young physicians seeking careers in radiationon-cology may have severely limited employment opportunities inthe foreseeable future, according to the American College of RadiationOncology (ACRO). The College forecasts that up to 1,000 radiationoncologists will be either underemployed or unemployed shortlyafter the year 2000.
The College's Personnel Needs Assessment Committee found thatapproximately 800 new radiation oncologists will enter the jobmarket in the next 5 years while fewer than 200 existing radiationoncologists will leave the workforce during the same period.
Quality of Training Affected
The Committee anticipates that the annual average caseload isexpected to remain between 210 and 216 patients through the year2004. A surplus of radiation oncologists may decrease patientcaseload at large medical centers and limit the number of patientsavailable for resident training, thereby adversely affecting thequality of training available to radiation oncology residents.
"The word needs to get out," said ACRO president WilliamD. Bloomer. "Unlike medical subspecialists who can fall backon general internal medicine if their specialty practice falters,radiation oncologists have no fall-back position without majorre-training."
FDA Approves Encorafenib/Cetuximab Plus mFOLFOX6 for Advanced BRAF V600E+ CRC
December 20th 2024The FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.
